The next era in treating mantle cell lymphoma will use precision medicine to target therapies in a personalized way, said Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at MD Anderson.
The next era in treating mantle cell lymphoma will use precision medicine to target therapies in a personalized way, said Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at MD Anderson.
Transcript
How have next-generation sequencing and assessments of minimal residual disease changed how MCL is treated?
I really think the therapy for mantle cell lymphoma has migrated from the chemotherapy era to the targeted therapy era now to the cell therapy era. But what if in the future when you give all these therapies, you still are not able to cure some patients? In other words, you are going to face some patients in the clinic who got all the therapies—targeted, chemo, cell therapies—and they still have disease. “Dr Wang, what are you going to do this time?”
I really think the next era is going to be the precision medicine era. The precision medicine era is not all about the sequencing, but indeed it started with the sequencing. Both DNA and RNA, and epigenetics, and also in the future proteomics. Now, sequencing is not all part of precision medicine. You have to have biomechanism studies and to find out, using sequencing and the biomechanism studies, find out the resistance mechanism in each particular patient. And then you can deliver the therapy directly to kill the Achilles’ heel of the cancer.
And I really think in the future, sequencing is going to be ubiquitous. It should be on every patient. It should be utilized with the biomechanisms for precision medicine in a personalized manner.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More